DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,046 filers reported holding DANAHER CORPORATION in Q3 2016. The put-call ratio across all filers is 0.17 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $463,947 | +46.0% | 1,870 | +41.2% | 0.08% | +47.1% |
| Q2 2023 | $317,760 | -13.6% | 1,324 | -9.3% | 0.05% | -20.3% |
| Q1 2023 | $367,726 | -26.5% | 1,459 | -22.6% | 0.06% | -30.4% |
| Q4 2022 | $500,051 | +30.6% | 1,884 | +27.2% | 0.09% | +13.6% |
| Q3 2022 | $383,000 | +20.1% | 1,481 | +17.5% | 0.08% | +22.7% |
| Q2 2022 | $319,000 | -21.6% | 1,260 | -9.3% | 0.07% | -10.8% |
| Q1 2022 | $407,000 | +30.4% | 1,389 | +46.7% | 0.07% | +29.8% |
| Q4 2021 | $312,000 | -5.5% | 947 | -12.6% | 0.06% | -17.4% |
| Q3 2021 | $330,000 | +26.4% | 1,084 | +11.5% | 0.07% | +25.5% |
| Q2 2021 | $261,000 | +27.3% | 972 | +6.5% | 0.06% | +25.0% |
| Q1 2021 | $205,000 | -49.3% | 913 | -49.7% | 0.04% | -6.4% |
| Q4 2020 | $404,000 | +110.4% | 1,816 | +104.0% | 0.05% | -11.3% |
| Q3 2020 | $192,000 | +25.5% | 890 | +2.7% | 0.05% | +10.4% |
| Q2 2020 | $153,000 | +54.5% | 867 | +21.1% | 0.05% | +26.3% |
| Q1 2020 | $99,000 | -22.0% | 716 | -13.6% | 0.04% | -20.8% |
| Q4 2019 | $127,000 | +7.6% | 829 | +1.7% | 0.05% | 0.0% |
| Q3 2019 | $118,000 | +38.8% | 815 | +37.4% | 0.05% | +41.2% |
| Q2 2019 | $85,000 | +10.4% | 593 | +1.4% | 0.03% | 0.0% |
| Q1 2019 | $77,000 | +185.2% | 585 | +123.3% | 0.03% | +126.7% |
| Q4 2018 | $27,000 | -10.0% | 262 | -4.4% | 0.02% | +7.1% |
| Q3 2018 | $30,000 | +3.4% | 274 | -5.2% | 0.01% | 0.0% |
| Q2 2018 | $29,000 | +7.4% | 289 | +6.6% | 0.01% | -17.6% |
| Q1 2018 | $27,000 | +42.1% | 271 | +30.9% | 0.02% | +41.7% |
| Q4 2017 | $19,000 | +5.6% | 207 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $18,000 | +5.9% | 207 | 0.0% | 0.01% | +9.1% |
| Q2 2017 | $17,000 | 0.0% | 207 | +1.5% | 0.01% | -8.3% |
| Q1 2017 | $17,000 | +6.2% | 204 | 0.0% | 0.01% | +9.1% |
| Q4 2016 | $16,000 | 0.0% | 204 | 0.0% | 0.01% | -15.4% |
| Q3 2016 | $16,000 | -23.8% | 204 | 0.0% | 0.01% | -27.8% |
| Q2 2016 | $21,000 | +10.5% | 204 | 0.0% | 0.02% | +5.9% |
| Q1 2016 | $19,000 | 0.0% | 204 | 0.0% | 0.02% | 0.0% |
| Q4 2015 | $19,000 | +11.8% | 204 | 0.0% | 0.02% | +13.3% |
| Q3 2015 | $17,000 | 0.0% | 204 | 0.0% | 0.02% | +7.1% |
| Q2 2015 | $17,000 | 0.0% | 204 | 0.0% | 0.01% | 0.0% |
| Q1 2015 | $17,000 | 0.0% | 204 | 0.0% | 0.01% | +16.7% |
| Q4 2014 | $17,000 | – | 204 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |